Back to results
US 11,992,479 B2Granted
R-fadrozole for use in the treatment of aldostonerism
AssigneeDamian Pharma AG
InventorsRonald Edward Steele, Christoph Schumacher
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeDamian Pharma AG
InventorsRonald Edward Steele, Christoph Schumacher
Estimating the term…
The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said disease or disorder, said composition comprises a compound which is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine or a pharmaceutically acceptable salt thereof, wherein preferably said compound is (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, and wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 97%, and wherein said composition is administered once daily to a subject in need thereof. The invention further relates to a pharmaceutical composition comprising a daily dosage of said compound in a fixed-unit dosage form and to a combination comprising (i) said pharmaceutical composition or said compound; and (ii) instructions for administration of said pharmaceutical composition or said compound once per day.
A method of treating a disease or disorder selected from primary aldosteronism and secondary aldosteronism in human a subject in need thereof, the method comprising orally administering once daily to said subject a therapeutically effective amount of a composition comprising 4 mg or 8 mg of a compound which is R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazo[1,5-a]pyridine dihydrogen phosphate, wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 99%.
A method of treating primary aldosteronism in a human subject in need thereof, the method comprising orally administering to the subject 4 mg of the compound (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, once daily, wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 99%.
A method of treating primary aldosteronism in a human subject in need thereof, the method comprising orally administering to the subject 8 mg of the compound (R)-(+)-5-(p-cyanophenyl)-5,6,7,8-tetrahydroimidazolium[1,5-a]pyridine dihydrogen phosphate, once daily, wherein said compound has an enantiomeric excess (ee) of the (R) form higher than or equal to 99%.
Dependencies are inferred from the claim text.